Roche announced today that it would be selling worldwide rights to three products to the Actavis, the Icelandic generics firm.
The products are Bezalip (a lipid metabolism regulator), Rapilysin (for acute myocardial infarctions) and Neotigason (treats psoriasis and other skin disorders). Actavis is expected to begin selling the products worldwide in 2008. Roche will continue to sell the drugs in Latin America, under a license from Actavis.
The combined sales for all products are just over $100 million. However, it allows Roche to continue focusing in oncology and other high-growth fields.